Veracyte (VCYT) Tops Q2 EPS by 12c

Veracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.13), $0.12 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $55.1 million versus the consensus estimate of $48.06 million.

GUIDANCE:

Veracyte sees FY2021 revenue of $200-208 million, versus the consensus of $197.9 million.

For earnings history and earnings-related data on Veracyte (VCYT) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Arca Biopharma (ABIO) Reports Q1 Loss of $0.14
• Utah Medical Products (UTMD) Reports Q1 EPS of $1.10